生产企业：Lundbeck
Asedebart (Lu AG13909) is Lundbeck's investigational humanized anti-ACTH monoclonal antibody in development for endogenous Cushing's syndrome, Cushing's disease and classic congenital adrenal hyperplasia (CAH). The U.S. FDA has granted it Orphan Drug Designation for endogenous Cushing's syndrome.
Asedebart (Lu AG13909) is Lundbeck's investigational humanized anti-ACTH monoclonal antibody in development for endogenous Cushing's syndrome, Cushing's disease and classic congenital adrenal hyperplasia (CAH). The U.S. FDA has granted it Orphan Drug Designation for endogenous Cushing's syndrome.
Asedebart is a humanized anti-ACTH monoclonal antibody that specifically recognizes ACTH with high affinity. It blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands and thereby inhibits the neurohormonal signalling of ACTH. This inhibition reduces secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands.
共 3 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
